{
  "url": "https://openlegislation.uk/eu-regulation-2013-116/introduction",
  "json_url": "https://openlegislation.uk/eu-regulation-2013-116/introduction.json",
  "legislation": "eur/2013/116",
  "legislation_title": "Commission Implementing Regulation (EU) No 116/2013 of 8 February 2013 amending the Annex to Regulation (EU) No 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, as regards the substance eprinomectin (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2013-116",
  "path": "introduction",
  "kind": "introduction",
  "number": null,
  "heading": "Introductory text",
  "text": "Commission Implementing Regulation (EU) No 116/2013\nof 8 February 2013\namending the Annex to Regulation (EU) No 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, as regards the substance eprinomectin\n(Text with EEA relevance)\nTHE EUROPEAN COMMISSION,\nHaving regard to the Treaty on the Functioning of the European Union,\nHaving regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council, and in particular Article 14 in conjunction with Article 17 thereof,\nHaving regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,\nWhereas:\n(1)\nThe maximum residue limit (hereinafter ‘MRL’) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry should be established in accordance with Regulation (EC) No 470/2009.\n(2)\nPharmacologically active substances and their classification regarding MRLs in foodstuffs of animal origin are set out in the Annex to Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin.\n(3)\nEprinomectin is currently included in Table 1 of the Annex to Regulation (EU) No 37/2010 as an allowed substance, for bovine species, applicable to muscle, fat, liver kidney and milk.\n(4)\nAn application for the extension of the existing entry for eprinomectin applicable to ovine species has been submitted to the European Medicines Agency.\n(5)\nAccording to Article 5 of Regulation (EC) No 470/2009 the European Medicines Agency is to consider using MRLs established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or MRLs established for a pharmacologically active substance in one or more species for other species. The Committee for Medicinal Products for Veterinary Use recommended the establishment of a provisional MRL for eprinomectin for ovine species, applicable to muscle, fat, liver, kidney and milk, and the extrapolation of the MRLs for eprinomectin from ovine and bovine species, applicable to muscle, fat, liver, kidney and milk to caprine species, establishing a provisional MRL, applicable to muscle, fat, liver, kidney and milk.\n(6)\nThe CVMP recommended the establishment of a provisional MRL for ovine and caprine species as the scientific data is incomplete for the proposed analytical method for monitoring residues in ovine and caprine species.\n(7)\nThe entry for eprinomectin in Table 1 of the Annex to Regulation (EU) No 37/2010 should therefore be amended to include the provisional MRLs for ovine and caprine species, applicable to muscle, fat, liver, kidney and milk. The provisional MRLs set out in that Table for ovine and caprine species should expire on 1 July 2014.\n(8)\nIt is appropriate to provide for a reasonable period of time for the stakeholders concerned to take measures that may be required to comply with the newly set MRL.\n(9)\nThe measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,\nHAS ADOPTED THIS REGULATION:",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "OJ L 152, 16.6.2009, p. 11."
    },
    {
      "type": "footnote",
      "label": "f2",
      "text": "OJ L 15, 20.1.2010, p. 1."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2013/116/introduction",
    "retrieved_at": "2026-11-01T14:48:51.865187+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}